Biogen Idec news from FierceBiotech
NewsEnzon spins off biotech ops into $150M enterprise
Enzon Pharmaceuticals has decided to spin off its biotech operations into a new company, adopting a suggestion floated by none other than Carl Icahn. Icahn has Read more...
CEO pay: Who makes what in Big Biotech?
What do you get when you make it to the top of of Big Biotech's biggest companies? Millions in compensation, for one thing. But although the average pay for the CEOs listed is $14.42 million, most Read more...
Rituxan fails (again) in late-stage lupus trial
Genentech and Biogen Idec were taking it on the chin this morning after researchers announced that Rituxan had failed in a later-stage trial as a therapy for lupus. The failure won't harm the Read more...
Biogen Idec CEO James Mullen - CEO pay report
James Mullen - Biogen Idec Total Compensation: $8.9 million Details: Mullen garnered $1.14 million in base salary, $1.94 million in incentives and $159,625 in other compensation. Most of Mullen's Read more...
Mass. biotechs ripe for buyouts
Recently, GSK forked over $720 million for Sirtris Pharmaceuticals and Japan's Takeda made an Read more...
Biogen squares off against Icahn in board battle
The war between Biogen Idec and Wall Street raider Carl Icahn is heating up. The Boston-based biotech has Read more...
ALSO NOTED: FDA approves Orencia; Delay on Amgen clotting drug decision; Icahn files suit for Biogen Idec papers; and much more
> The FDA has approved Bristol-Myers Squibb's Orencia for juvenile arthritis. Read more...
Biogen Idec - Big Biotech's Stock Report
Company: Biogen Idec Starting stock price: $49.75 Ending stock price: $57.48 Percent Change: 16.26% Scoop: Biogen Idec had quite the year. Let's look at the clinical side of things first. A Phase II Read more...
Big Biotech's Stock Report
2007 was a big year for Big Biotech, and while some of the top companies shined, other industry leaders took a beating. Biotech five biggest players--Amgen (1), Genentech (2), Biogen Idec (3), Read more...
Dutch biotech gains $34M for clinical work
The Dutch biotech PanGenetics has rounded up $34 million in venture backing for the clinical development of two antibody programs. The round was led by Edmond de Rothschild Investment Partners with Read more...
| Press ReleasesBiogen Idec Announces First Startup in Its Innovation Incubator Biogen Idec Announces First Startup in Its Innovation Incubator Initiative Designed to Contribute to Productivity of Early-Stage Pipeline First Project Leverages Original Finding by Columbia Read more... PRESS RELEASE: Biogen Idec completes Review of Strategic Alternatives BIOGEN IDEC COMPLETES REVIEW OF STRATEGIC ALTERNATIVES Company to Remain Independent Cambridge, MA, December 12, 2007 - The Board of Directors of Biogen today announced that, after completing a Read more... PRESS RELEASE: Biogen Idec and Neurimmune Announce $380M Alliance to Develop Treatments for Alzheimer's Diseases Biogen Idec and Neurimmune Announce $380M Alliance to Develop Treatments for Alzheimer's Diseases Cambridge, MA and Zürich, Switzerland, November 20, 2007 – Biogen Idec and Neurimmune Read more... PRESS RELEASE: BIOGEN IDEC ISSUES STATEMENT BIOGEN IDEC ISSUES STATEMENT Cambridge, MA, October 12, 2007 - Biogen Idec today announced that its Board of Directors has authorized management to evaluate whether third parties would have an Read more... PRESS RELEASE: LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies LigoCyte Pharmaceuticals Announces Collaboration With Biogen Idec to Develop Anti-CD103 Therapies BOZEMAN, Mont., Sept. 18 -- LigoCyte Pharmaceuticals, Inc., today announced a strategic partnership Read more... |
Get more Biogen Idec coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight